New pill aims to tame lupus kidney damage

NCT ID NCT06717815

Recruiting now Disease control Sponsor: Nanjing Immunophage Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new daily pill, IPG11406, in 36 adults with lupus nephritis—a kidney complication of lupus. The study checks if the drug is safe and whether it can reduce protein in the urine and improve kidney function. It is too soon to know if it works, but the goal is to better control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPG11406 (a tablet that blocks a protein called GPR183 to reduce inflammation)
What this could lead to: If successful, this could point toward a new daily pill to control lupus nephritis and protect kidney function.
What could go wrong: This is a very early (Phase 1/2) trial with only 36 people, so it is primarily checking safety. It may not show clear benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Locations

Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, China
Fujian Provincial Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, China
Hebei Petro China Central Hospital
TERMINATED

Langfang, Hebei, China
Jinhua Municipal Centeral Hospital Medical Group
RECRUITING

Jinhua, Zhejiang, China
Nanjing DrumTower Hospital of Nanjing University Medical School
RECRUITING

Nanjing, Jiangsu, 210008, China
Nantong First People's Hospital
RECRUITING

Nantong, Jiangsu, China
Renmin Hospital of Wuhan University
RECRUITING

Wuhan, Hubei, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China
Shandong Provincial Hospital
RECRUITING

Jinan, Shandong, China
Sun Yai-sen Memorial Hospital, Sun Yai-sen University
RECRUITING

Guangzhou, Guandong, China
The Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, Jiangsu, China
The First Affiliated Hospital Of Anhui Medical University
RECRUITING

Hefei, Anhui, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, China
West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, China
Wuhan Hospital of Traditional Chinese and Western Medicine
RECRUITING

Wuhan, Hubei, China
Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, China
Xinxiang Central Hospital
RECRUITING

Xinxiang, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.